A Case of Pyoderma Gangrenosum in a Patient with Rheumatoid Arthritis Treated with Abatacept

被引：6

作者：

Akahoshi-Ikeda, Maki ^{[1
]}

Yoshizawa, Seiji ^{[2
]}

Motoshita, Junichi ^{[3
]}

Fume, Masutaka ^{[4
]}

Takeuchi, Satoshi ^{[1
,4
]}

机构：

[1] Hamanomachi Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Dermatol, Chuo Ku, Nagahama 3-3-1, Fukuoka 8108539, Japan

[2] Hamanomachi Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Rheumatol, Chuo Ku, Nagahama 3-3-1, Fukuoka 8108539, Japan

[3] Hamanomachi Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Pathol, Chuo Ku, Nagahama 3-3-1, Fukuoka 8108539, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan

来源：

ACTA DERMATO-VENEREOLOGICA | 2016年 / 96卷 / 06期

关键词：

THERAPY; INFLAMMATION; INFLIXIMAB;

D O I：

10.2340/00015555-2380

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis induced by trauma or infection, which frequently appears on the lower legs. Various autoimmune diseases and systemic tumour necrosis factor (TNF)-α-blocking treatment cause PG, suggesting that T-cell-mediated reactions are involved in the aetiology. We report here for the first time a case of PG occurring during treatment with abatacept, a T-cell co-stimulation blocker. In addition, we discuss a possible underlying disease mechanism. © 2016 The Authors.

引用

页码：822 / 823

页数：2

共 16 条

[1] CTLA-4-Ig Therapy Diminishes the Frequency but Enhances the Function of Treg Cells in Patients with Rheumatoid Arthritis [J].

Alvarez-Quiroga, Crisol ;

Abud-Mendoza, Carlos ;

Doniz-Padilla, Lesly ;

Juarez-Reyes, Amida ;

Monsivais-Urenda, Adriana ;

Baranda, Lourdes ;

Gonzalez-Amaro, Roberto .

JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (04) :588-595

[2] Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population [J].

Anderson, DE ;

Bieganowska, KD ;

Bar-Or, A ;

Oliveira, EML ;

Carreno, B ;

Collins, M ;

Hafler, DA .

NATURE MEDICINE, 2000, 6 (02) :211-214

[3] Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients [J].

Binus, A. M. ;

Qureshi, A. A. ;

Li, V. W. ;

Winterfield, L. S. .

BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) :1244-1250

[4] T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking [J].

Brooklyn, T. N. ;

Williams, A. M. ;

Dunnill, M. G. S. ;

Probert, C. S. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (05) :960-966

[5] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial [J].

Brooklyn, TN ;

Dunnill, MGS ;

Shetty, A ;

Bowden, JJ ;

Williams, JDL ;

Griffiths, CEM ;

Forbes, A ;

Greenwood, R ;

Probert, CS .

GUT, 2006, 55 (04) :505-509

[6] Paradoxical Reactions to Targeted Biological Treatments: A Way to Treat and Trigger? [J].

Brunasso, Alexandra M. G. ;

Laimer, Martin ;

Massone, Cesare .

ACTA DERMATO-VENEREOLOGICA, 2010, 90 (02) :183-185

[7] T-HELPER-SUPPRESSOR CELL IMBALANCE IN PYODERMA GANGRENOSUM, WITH RELAPSING POLYCHONDRITIS AND CORNEAL KERATOLYSIS [J].

CHECK, IJ ;

ELLINGTON, EP ;

MORELAND, A ;

MCKAY, M .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1983, 80 (03) :396-399

[8] Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].

Choy, EHS ;

Panayi, GS .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916

[9] Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis [J].

Collamer, Angelique N. ;

Battafarano, Daniel F. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (03) :233-240

[10] CD8+ T Cells Mediate RAS-Induced Psoriasis-Like Skin Inflammation through IFN-γ [J].

Gunderson, Andrew J. ;

Mohammed, Javed ;

Horvath, Frank J. ;

Podolsky, Michael A. ;

Anderson, Cherie R. ;

Glick, Adam B. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (04) :955-963

← 1 2 →